Neupro for Restless Legs Syndrome

UCB Pharma has launched two new strengths of Neupro (rotigotine) transdermal patches 1mg/24hr and 3mg/24hr. These additional strengths can be used alongside the existing 2mg/24hr patch in the management of moderate to severe idiopathic restless legs syndrome.

Treatment should be initiated using a 1mg/24hr patch daily and increased according to patient response in weekly increments of 1mg/24hr until an effective dose is reached or the maximal dose of 3mg/24hr is reached.

The need for treatment continuation should be reconsidered every six months.

The mechanism of action for rotigotine in restless legs syndrome is not fully understood.

View Neupro drug record

Further information: UCB Pharma

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases